on October 17, 2002
Published online before print October 17, 2002, doi: 10.1161/01.ATV.0000042081.57854.A2
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on September 10, 2002
Accepted on September 16, 2002
Influence of Factor VIIa and Phospholipids on Coagulation in "Acquired" Hemophilia
Saulius Butenas ;
From the University of Vermont, College of Medicine, Burlington, Vt.
* To whom correspondence should be addressed. E-mail: kmann{at}zoo.uvm.edu..
Objective—This study was performed to evaluate the influences of phospholipids and recombinant factor VIIa (rFVIIa) on thrombin generation and clot formation in "acquired" hemophilia B.
Methods and Results—A synthetic mixture corresponding to hemophilia A and "acquired" hemophilia B blood (AHBB) manufactured in vitro by an anti-FIX antibody were used in this study. With 10 pmol/L tissue factor (TF), 10 nmol/L rFVIIa, and saturating phospholipid, established thrombin generation in SHA was similar to that observed in the presence of factor VIII and rFVIIa at physiological concentrations. At lower phospholipid concentrations, thrombin generation was delayed and reduced. With 5 pmol/L TF, contact pathway-inhibited AHBB clotted later than normal blood and showed reduced clot stability and thrombin generation. These parameters of effectiveness were increased by the addition of phospholipids to AHBB, which restored clot stability and increased thrombin generation. No correction of clot formation or thrombin generation was observed when rFVIIa and phospholipids were added to AHBB in the absence of TF.
Conclusions—The influence of rFVIIa is dependent on TF, and phospholipids substantially increase the hemostatic (or thrombotic) potential of rFVIIa/TF.
Key words: hemophilia • factor VIIa • tissue factor • phospholipids • thrombin generation
This article has been cited by other articles:
 |
|
 |
|
  T. Orfeo, K. E. Brummel-Ziedins, M. Gissel, S. Butenas, and K. G. Mann The Nature of the Stable Blood Clot Procoagulant Activities J. Biol. Chem., April 11, 2008; 283(15): 9776 - 9786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Warren, K. Mandal, V. Hadjianastassiou, L. Knowlton, S. Panesar, K. John, A. Darzi, and T. Athanasiou Recombinant Activated Factor VII in Cardiac Surgery: A Systematic Review Ann. Thorac. Surg., February 1, 2007; 83(2): 707 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Orfeo, S. Butenas, K. E. Brummel-Ziedins, and K. G. Mann The Tissue Factor Requirement in Blood Coagulation J. Biol. Chem., December 30, 2005; 280(52): 42887 - 42896. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. R. Roberts, D. M. Monroe, and G. C. White The use of recombinant factor VIIa in the treatment of bleeding disorders Blood, December 15, 2004; 104(13): 3858 - 3864. [Abstract] [Full Text] [PDF]
|
|